Table 1 Major cancer immunotherapeutics approved by the US Food and Drug Administration (FDA)
From: New opportunities for nanoparticles in cancer immunotherapy
Drug (Trade Name) | Drug Type (Target) | Targeted Cancer | FDA Approval Date |
|---|---|---|---|
Ipilimumab (Yervoy®) | Monoclonal antibody (CTLA-4) | Advanced melanoma | March 2011 |
Pembrolizumab (Keytruda®) | Monoclonal antibody (PD-1) | Advanced refractory melanoma and non–small cell lung cancer | September 2014 |
Nivolumab (Opdivo®) | Monoclonal antibody (PD-1) | Unresectable or metastatic melanoma squamous non–small cell lung cancer | December 2014 |
Atezolizumab (Tecentriq®) | Monoclonal antibody (PD-L1) | Locally advanced or metastatic bladder cancer | May 2016 |
Avelumab (Bavencio®) | Monoclonal antibody (PD-L1) | Locally advanced or metastatic bladder cancer | May 2017 |
Durvalumab (Imfinzi®) | Monoclonal antibody (PD-L1) | Locally advanced or metastatic bladder cancer | May 2017 |